PPARA and catalepsy: We found that pretreatment with the selective PPARa antagonist GW6471 produced dose-dependent enhancement in Δ9-THC-induced catalepsy (Fig. 6A), a trend toward an increase in Δ9-THC-induced analgesia (Fig. 6B), but no effect on Δ9-THC-induced hypothermia or immobility (Figs. S7, S8).